(2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxy-3-phenylpropionamide (BiPS), a matrix metalloprotease inhibitor, is a novel and potent activator of hypoxia-inducible factors

Molecular Pharmacology

Volumn 74, Issue 1, 2008, Pages 282-288

  Lauzier, Marie Claude ^a   Robitaille, Geneviève A ^a   Chan, Denise A ^b   Giaccia, Amato J ^b   Richard, Darren E ^a  

^a LAVAL UNIVERSITY   (Canada)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BIPHENYLSULFONYLAMINO N HYDROXY 3 PHENYLPROPIONAMIDE; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MATRIX METALLOPROTEINASE INHIBITOR; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; HYDROXYLATION; HYPOXIA; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT;

ANIMALS; AORTA, THORACIC; CATTLE; CELL HYPOXIA; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, REPORTER; HELA CELLS; HUMANS; HYDROXAMIC ACIDS; HYPOXIA-INDUCIBLE FACTOR 1; KINETICS; LUCIFERASES, FIREFLY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 45749093735     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.045690     Document Type: Article

References (41)

1. Blouin CC, Page EL, Soucy GM, and Richard DE (2004) Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha. Blood 103:1124-1130.
2. Chan DA, Sutphin PD, Yen SE, and Giaccia AJ (2005) Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 25:6415-6426.
3. Deem TL and Cook-Mills JM (2004) Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species. Blood 104:2385-2393.
4. Dwivedi DJ, Pino G, Banh A, Nathu Z, Howchin D, Margetts P, Sivak JG, and West-Mays JA (2006) Matrix metalloproteinase inhibitors suppress transforming growth factor-beta-induced subcapsular cataract formation. Am J Pathol 168:69-79.
5. Ebert BL, Firth JD, and Ratcliffe PJ (1995) Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 270:29083-29089.
6. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, and Arbeit JM. (2001) Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 15:2520-2532.
7. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, and Fujii-Kuriyama Y (1997) A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A 94:4273-4278.
8. Fears CY, Grammer JR, Stewart JE Jr, Annis DS, Mosher DF, Bornstein P, and Gladson CL (2005) Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model. Cancer Res 65:9338-9346.
9. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611.
10. Fish WW (1988) Rapid colorimetric micromethod for the quantitation of complexed iron in biological samples. Methods Enzymol 158:357-364.
11. Flamme I, Frohlich T, von Reutern M, Kappel A, Damert A, and Risau W (1997) HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev 63:51-60.
12. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, and Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613.
13. Gu YZ, Moran SM, Hogenesch JB, Wartman L, and Bradfield CA (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7:205-213.
14. Hewitson KS and Schofield CJ (2004) The HIF pathway as a therapeutic target. Drug Discov Today 9:704-711.
15. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, Perdew GH, and Bradfield CA. (1997) Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 272:8581-8593.
16. Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, Lin A, Smith R, Rodgers GP, Donahue RE, et al. (2007) HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110:2140-2147.
17. Kasiganesan H, Sridharan V, and Wright G (2007) Prolyl hydroxylase inhibitor treatment confers whole-animal hypoxia tolerance. Acta Physiol (Oxf) 190:163-169.
18. Khan TA, Sellke FW, and Laham RJ (2003) Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 10:285-291.
19. Lauzier MC, Page EL, Michaud MD, and Richard DE (2007) Differential regulation of hypoxia-inducible factor-1 through receptor tyrosine kinase transactivation in vascular smooth muscle cells. Endocrinology 148:4023-4031.
20. Lee KS, Jin SM, Kim SS, and Lee YC (2004) Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol 113:902-909.
21. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg RD, et al. (2000) PR39, a peptide regulator of angiogenesis. Nat Med 6:49-55.
22. Lin SJ, Lee IT, Chen YH, Lin FY, Sheu LM, Ku HH, Shiao MS, Chen JW, and Chen YL (2007) Salvianolic acid B attenuates MMP-2 and MMP-9 expression in vivo in apolipoprotein-E-deficient mouse aorta and in vitro in LPS-treated human aortic smooth muscle cells. J Cell Biochem 100:372-384.
23. Liu Y, Cox SR, Morita T, and Kourembanas S (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 77:638-643.
24. Mahon PC, Hirota K, and Semenza GL (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15:2675-2686.
25. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, and Poellinger L (2001) Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414:550-554.
26. Makino Y, Kanopka A, Wilson WJ, Tanaka H, and Poellinger L (2002) Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3α locus. J Biol Chem 277:32405-32408.
27. Mazure NM, Chen EY, Yeh P, Laderoute KR, and Giaccia AJ (1996) Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 56:3436-3440.
28. McDonough MA, Li V, Flashman E, Chowdhury R, Mohr C, Lienard BM, Zondlo J, Oldham NJ, Clifton IJ, Lewis J, et al. (2006) Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci U S A 103:9814-9819.
29. Owens GK, Loeb A, Gordon D, and Thompson MM (1986) Expression of smooth muscle-specific alpha-isoactin in cultured vascular smooth muscle cells: relationship between growth and cytodifferentiation. J Cell Biol 102:343-352.
30. Richard DE, Berra E, Gothie E, Roux D, and Pouyssegur J (1999) p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 274:32631-32637.
31. Salnikow K, Donald SP, Bruick RK, Zhitkovich A, Phang JM, and Kasprzak KS (2004) Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 279:40337-40344.
32. Schofield CJ and Ratcliffe PJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5:343-354.
33. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732.
34. Semenza GL and Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447-5454.
35. Shyu KG, Wang MT, Wang BW, Chang CC, Leu JG, Kuan P, and Chang H (2002) Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infection model in the rat. Cardiovasc Res 54:576-583.
36. Simons M and Ware JA (2003) Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2:863-871.
37. Stookey L (1970) Ferrozine-A new spectrophotometric reagent for iron. Anal Chem 42:779-781.
38. Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, et al. (1998) Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem 41:640-649.
39. Tian H, McKnight SL, and Russell DW (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11:72-82.
40. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, Goldberg MA, Akita GY, Gregory RJ, and Isner JM (2000) Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 102:2255-2261.
41. Willam C, Masson N, Tian YM, Mahmood SA, Wilson MI, Bicknell R, Eckardt KU, Maxwell PH, Ratcliffe PJ, and Pugh CW (2002) Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis. Proc Natl Acad Sci U S A 99:10423-10428.